Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
4.26Last Year’s EPS
4.76Same Quarter Last Year
Moderate Buy
Based on 27 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 10, 2025
|% Change Since: 2.20%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and successful product launches, signaling a positive momentum for Vertex's commercial and R&D efforts. However, the call also acknowledged challenges such as IP violations in Russia and increased operating expenses affecting profitability.Company Guidance
During the Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call, the company provided guidance for 2025, projecting total revenue between $11.75 billion and $12 billion, representing approximately 8% growth at the midpoint. The growth is expected to be driven primarily by continued expansion in the cystic fibrosis (CF) portfolio, particularly in the U.S., bolstered by the launch of ALYFTREK, a new CFTR modulator. International CF revenue growth will be impacted by a reduction in one country where intellectual property rights are being violated. The guidance also includes revenue contributions from the ongoing global launch of CASGEVY and the recent U.S. launch of JOURNAVX, with its impact primarily in the latter half of the year. Vertex expects to maintain robust R&D investments, with combined non-GAAP R&D, acquired IPR&D, and SG&A expenses projected at $4.9 billion to $5 billion, reflecting ongoing pivotal studies and commercial launch support. The company also anticipates a non-GAAP effective tax rate between 20.5% and 21.5% for the full year.Record Revenue Growth
Vertex Pharmaceuticals reported $2.91 billion in revenue for Q4 2024, marking a 16% increase compared to Q4 2023. Full-year 2024 revenue reached $11.02 billion, a 12% increase over 2023, marking the 10th consecutive year of double-digit growth.
Successful New Product Launches
The company launched ALYFTREK, CASGEVY, and JOURNAVX, with positive feedback from healthcare professionals and patients. JOURNAVX, in particular, was highlighted as the first new class of pain medication in over 20 years.
Strong Pipeline and R&D Progress
Vertex continued to advance its pipeline, including promising developments in CF, type 1 diabetes, renal diseases, and pain management. Notable progress includes pivotal studies for zimislecel, povetacicept, and inaxaplin.
Strategic Leadership Transition
Leadership transitions were announced with confidence in the planned succession, including Charlie Wagner assuming the role of COO and Duncan McKechnie as Chief Commercial Officer.
---
VRTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VRTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 10, 2025 | $469.97 | $455.22 | -3.14% |
| Nov 04, 2024 | $472.80 | $499.88 | +5.73% |
| Aug 01, 2024 | $505.78 | $494.46 | -2.24% |
| May 06, 2024 | $402.50 | $410.24 | +1.92% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Vertex Pharmaceuticals (VRTX) report earnings?
Vertex Pharmaceuticals (VRTX) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Vertex Pharmaceuticals (VRTX) earnings time?
Vertex Pharmaceuticals (VRTX) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VRTX EPS forecast?
VRTX EPS forecast for the fiscal quarter 2025 (Q1) is 4.26.
---